ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
0
246
331
91
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
91
Operating Expenses
Research Development
103,665
132,167
79,419
93,832
87,718
Selling General and Administrative
51,201
30,100
23,667
24,758
18,187
Total Operating Expenses
154,866
162,267
103,086
118,590
105,905
Operating Income or Loss
-154,866
-162,267
-102,840
-118,259
-105,814
Interest Expense
-
0
0
37
-
Total Other Income/Expenses Net
-
-
-
0
0
Income Before Tax
-147,886
-155,126
-98,834
-115,361
-104,792
Income Tax Expense
2
2
-1,061
1,066
2
Income from Continuing Operations
-147,887
-155,127
-97,773
-116,426
-104,793
Net Income
-147,887
-155,127
-97,773
-116,426
-104,793
Net Income available to common shareholders
-147,887
-155,127
-97,773
-116,426
-104,793
Reported EPS
Basic
-
-2.84
-2.12
-2.69
-2.91
Diluted
-
-2.84
-2.12
-2.69
-2.91
Weighted average shares outstanding
Basic
-
54,708
46,182
43,240
36,069
Diluted
-
54,708
46,182
43,240
36,069
EBITDA
-
-154,757
-98,620
-115,127
-105,674